Efficacy and Safety of Azimilide for the Treatment of Patients With Atrial Fibrillation
Atrial Fibrillation
About this trial
This is an interventional treatment trial for Atrial Fibrillation
Eligibility Criteria
Inclusion criteria: Documented (12-lead ECG) history of symptomatic atrial fibrillation occurring between 48 hours and 6 months before screening Require the procedure of cardioversion (electric shock to correct heart rhythm) In the investigator's opinion, be likely to maintain sinus rhythm after cardioversion. Be anticoagulated according to the recommendations of the Study Group on Atrial Fibrillation of the European Society of Cardiology guidelines. Exclusion criteria: Previously unsuccessful electrical cardioversions Failed to respond to any Class III antiarrhythmic drugs Qualifying arrhythmia due to acute reversible illness, acute myocardial infarction, and/or cardiac or thoracic surgery within one month prior to randomization
Sites / Locations
- The Heart Group, PC
- University Medical Center
- Cardiovascular Associates of Penisula
- San Diego Cardiovascular Research Associates
- La Mesa Cardiac Center, a Medical Group
- Good Samaritan Hospital
- LAC + USC Medical Center
- Cardiology Section, West Los Angeles VA Hospital
- Merced Heart Associates
- Sutter Gould Medical Foundation
- ARI Clinical Trials
- Inland Clinical Research
- Regional Cardiology Assoc.
- Cardiology Associates
- Western Cardiology Assoc.
- Hartford Hospital
- The George Washington University MFA
- Cardiology Consultants
- C/O Research Office Attn: Cardiovascular Research Dept.
- Jacksonville Center for Clinical Research
- Lakeland Regional Medical
- Khalid Hasan Sheikh 80 Fortenberry Road
- Florida Cardiology
- Cardiology Reasearch Assiocates
- VA Medical Center
- Elgin Cardiology Associates
- Advocate Christ Medical Center
- Heart Center Medical Group
- The Care Group
- University of Louisville-Cardiology
- Louisville Cardiology Medical Group, P.S.C.
- Cardiovascular Institute of the South
- Richard Gilmore 501 S. Ryan Street
- Cardiovascular Instiute of the South
- Tulane University
- Androscoggin Cardiology Associates Research
- Maine Medical Center
- University of Massachusett
- Thoracic & Cardiovascular Healthcare Foundation
- Riverside Osteopathic Hospital
- Regional Heart Center
- VA Medical Center Therapeutic Section
- St. Paul Heart Clinic
- Duke Medical Center
- Altru Health System Research Center
- Lindner Clinical Trial Ctr.
- University Hospitals of Cleveland
- Hillsboro Cardiology
- Oregon Health Sciences University
- Heart Care Group PC
- Tri-State Medical Group Cardiology
- Milton S. Hershey Medical Center
- The Pavillion
- UPHS/Presbyterian Medical Center
- Cardiovascular and Critical Care Associates, P.C.
- Cardiology Foundation of Lankenau
- Charleston Cardiology
- Stern Cardiovascular Center Research Department
- UT Southwestern Medical Center
- Methodist Hospital
- Heart and Vascular Inst. of Texas, PA
- Riverside Regional Medical Center
- Daniel Gottlieb 16259 Sylvester Road SW Suite 401
- FHS Research
- Beloit Clinic, SC
- Wisconsin Center for Clinical Research
- Dean/Riverview Clinic
- University of Wisconsin Madison
- Wisconsin Center for Clinical Research
- University of Calgary
- Rockyview General Hospital CV Lab Research
- Cardiology Research St. Paul's Hospital
- Health Sciences Centre
- Hamilton Health Sciences Crop
- Cardiac Investigation Unit
- University of Ottawa Heart Institute
- Neureka Research Corporation
- St. Michael's Hospital
- Montreal Heart Institute
- Recherche Cardiologie
- Hospital Sacre-Coeur de Montreal
- Quebec Heart Institute
Arms of the Study
Arm 1
Arm 2
Placebo Comparator
Experimental
1
2
placebo tablets in hospital and placebo tablets outpatient
Azimilide tablets in hospital and azimilide tablets outpatient